Search
BioCryst Pharmaceuticals Inc
BCRXAdd to Watchlist
8.980USD
-0.260-2.81%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.28BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of BioCryst Pharmaceuticals Inc is 8.60, ranking 97 out of 385 in the Biotechnology & Medical Research industry. The average price target is 21.00, with a high of 30.00 and a low of 9.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
21.800
Target Price
+142.76%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
BioCryst Pharmaceuticals Inc
BCRX
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is BioCryst Pharmaceuticals Inc's expected revenue for the next quarter?
BioCryst Pharmaceuticals Inc's expected revenue is 182.51M.
What is BioCryst Pharmaceuticals Inc's price target?
Analysts forecast that BioCryst Pharmaceuticals Inc's price target is USD 21.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 9.00.
How have BioCryst Pharmaceuticals IncBCRX's recent earnings per share performed?
The market expectation was USD -2.98, while BioCryst Pharmaceuticals IncBCRX's earnings per share (EPS) for the previous quarter was USD 1.17. EPS for the next quarter is expected at USD 0.12.
What is the analyst rating for BioCryst Pharmaceuticals Inc?
Based on the ratings of BioCryst Pharmaceuticals Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.